TriSalus Life Sciences, Inc., founded in 2009 and headquartered in Westminster, Colorado Overview
Pro stress-test →TriSalus Life Sciences is an oncology-focused medical technology company engaged in research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. The company seeks to transform outcomes for patients with solid tumors by integrating innovative delivery technology with standard-of-care therapies and investigational immunotherapy.
Strategic Profile
Pro stress-test →TriSalus has two FDA-cleared devices using proprietary Pressure-Enabled Drug Delivery (PEDD) approach that modulates pressure and flow to deliver more therapeutic to the tumor while reducing undesired delivery to normal tissue. The company is developing nelitolimod, an investigational immunotherapeutic designed to treat the immunosuppressive environment created by tumors, with patient data from PERIO clinical trials supporting favorable immune effects.
Competitive Landscape
Pro stress-test →Nkarta Therapeutics is identified as a competitor of TriSalus Life Sciences. TriSalus operates in the oncology medical device space with proprietary drug delivery technology targeting difficult-to-treat solid tumors, a relatively specialized niche competing against both larger pharmaceutical companies and emerging biotech firms focused on immuno-oncology.
Industry Context
TriSalus Life Sciences, Inc., founded in 2009 and headquartered in Westminster, Colorado operates in Medical Devices & Oncology/Immuno-oncology.
Key facts
Founded: 2009 · Headquarters: Westminster, Colorado, US · Revenue: $40.2M · Market cap: $298M